Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy decreases lean body mass and appendicular skeletal muscle mass index even until one year after the final treatment in patients with B-cell non-Hodgkin lymphoma

References

• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–391. doi: 10.1016/S1470-2045(06)70664-7.
   PubMed Web of Science ®Google Scholar
• Park YH, Lee JJ, Ryu MH, et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol. 2006;85(4):257–262. doi: 10.1007/s00277-005-0060-6.
   PubMed Web of Science ®Google Scholar
• Swenson WT, Wooldridge JE, Lynch CF, et al. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2005;23(22):5019–5026. doi: 10.1200/JCO.2005.04.503.
   PubMed Web of Science ®Google Scholar
• Chu MP, Lieffers J, Ghosh S, et al. Skeletal muscle density is an independent predictor of diffuse large B-cell lymphoma outcomes treated with rituximab-based chemoimmunotherapy. J Cachexia Sarcopenia Muscle. 2017;8(2):298–304. doi: 10.1002/jcsm.12161.
   PubMed Web of Science ®Google Scholar
• Go S-I, Park MJ, Song H-N, et al. Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Cachexia Sarcopenia Muscle. 2016;7(5):567–576. doi: 10.1002/jcsm.12115.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Hara T, Shibata Y, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol. 2015;94(12):2043–2053. doi: 10.1007/s00277-015-2499-4.
   PubMed Web of Science ®Google Scholar
• Lanic H, Kraut-Tauzia J, Modzelewski R, et al. Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma. 2014;55(4):817–823. doi: 10.3109/10428194.2013.816421.
   PubMed Web of Science ®Google Scholar
• Shachar SS, Williams GR, Muss HB, et al. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58–67. doi: 10.1016/j.ejca.2015.12.030.
   PubMed Web of Science ®Google Scholar
• Cruz-Jentoft AJ, Gonzalez MC, Prado CM. Sarcopenia not equal low muscle mass. Eur Geriatr Med. 2023;14(2):225–228. doi: 10.1007/s41999-023-00760-7.
   PubMed Web of Science ®Google Scholar
• Shimizu N, Ngayama D, Watanabe Y, et al. Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) therapy increases carotid intima-media thickness and plaque score with von Willebrand factor activity elevation in patients with malignant lymphoma. J Chemother. 2022;34(4):258–263. doi: 10.1080/1120009X.2021.1988202.
   PubMed Web of Science ®Google Scholar
• Uchida S, Kamiya K, Hamazaki N, et al. Association between sarcopenia and atherosclerosis in elderly patients with ischemic heart disease. Heart Vessels. 2020;35(6):769–775. doi: 10.1007/s00380-020-01554-8.
   PubMed Web of Science ®Google Scholar
• Lai Z, Wu G, Yang Y, et al. Interactive effects of physical activity and sarcopenia on incident ischemic heart disease: results from a nation-wide cohort study. Atherosclerosis. 2023;388:117396. doi: 10.1016/j.atherosclerosis.2023.117396.
   PubMed Web of Science ®Google Scholar
• Barbalho SM, Flato UAP, Tofano RJ, et al. Physical Exercise and Myokines: relationships with Sarcopenia and Cardiovascular Complications. Int J Mol Sci. 2020;21(10):3607. doi: 10.3390/ijms21103607.
   PubMed Web of Science ®Google Scholar
• Cho Y, Park H-S, Huh BW, et al. Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus. Diabetes Metab J. 2023;47(2):232–241. doi: 10.4093/dmj.2021.0355.
   PubMed Web of Science ®Google Scholar
• Sullivan PA, Still CD, Jamieson ST, et al. Evaluation of multi-frequency bioelectrical impedance analysis for the assessment of body composition in individuals with obesity. Obes Sci Pract. 2019;5(2):141–147. doi: 10.1002/osp4.321.
   PubMed Web of Science ®Google Scholar
• Walewski J, Paszkiewicz-Kozik E, Michalski W, et al. First-line R-CVP versus R-CHOP induction immunochemotherapy for indolent lymphoma with rituximab maintenance. A multicentre, phase III randomized study by the Polish Lymphoma Research Group PLRG4. Br J Haematol. 2020;188(6):898–906. doi: 10.1111/bjh.16264.
   PubMed Web of Science ®Google Scholar
• Ida S, Watanabe M, Karashima R, et al. Changes in body composition secondary to neoadjuvant chemotherapy for advanced esophageal cancer are related to the occurrence of postoperative complications after esophagectomy. Ann Surg Oncol. 2014;21(11):3675–3679. doi: 10.1245/s10434-014-3737-z.
   PubMed Web of Science ®Google Scholar
• Rier HN, Jager A, Sleijfer S, et al. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy. Breast. 2017;31:9–15. doi: 10.1016/j.breast.2016.10.014.
   PubMed Web of Science ®Google Scholar
• Antoun S, Lanoy E, Iacovelli R, et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer. 2013;119(18):3377–3384. doi: 10.1002/cncr.28218.
   PubMed Web of Science ®Google Scholar
• Hayashi N, Ando Y, Gyawali B, et al. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer. Oncol Rep. 2016;35(3):1727–1731. doi: 10.3892/or.2015.4475.
   PubMed Web of Science ®Google Scholar
• Rier HN, Kharagjitsing H, van Rosmalen J, et al. Prognostic impact of low muscle mass and low muscle density in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2020;61(7):1618–1626. doi: 10.1080/10428194.2020.1737686.
   PubMed Web of Science ®Google Scholar
• Tey SL, Huynh DTT, Berde Y, et al. Prevalence of low muscle mass and associated factors in community-dwelling older adults in Singapore. Sci Rep. 2021;11(1):23071. doi: 10.1038/s41598-021-02274-3.
   PubMed Web of Science ®Google Scholar
• Camus V, Lanic H, Kraut J, et al. Prognostic impact of fat tissue loss and cachexia assessed by computed tomography scan in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Eur J Haematol. 2014;93(1):9–18. doi: 10.1111/ejh.12285.
   PubMed Web of Science ®Google Scholar
• Berentzen T, Sørensen TIA. Effects of intended weight loss on morbidity and mortality: possible explanations of controversial results. Nutr Rev. 2006;64(11):502–507. doi: 10.1111/j.1753-4887.2006.tb00183.x.
   PubMed Web of Science ®Google Scholar
• Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr Opin Support Palliat Care. 2018;12(4):420–426. doi: 10.1097/SPC.0000000000000382.
   PubMed Web of Science ®Google Scholar
• Barreto R, Kitase Y, Matsumoto T, et al. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass. Sci Rep. 2017;7(1):14470. doi: 10.1038/s41598-017-15040-1.
   PubMedGoogle Scholar
• Knobel H, Loge JH, Nordøy T, et al. High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage. 2000;19(6):446–456. doi: 10.1016/s0885-3924(00)00144-5.
   PubMed Web of Science ®Google Scholar